Webinars/Videos

In these masterclass on demand videos, Prof Bhatt discusses Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial, then answers questions received from the audience.
This masterclass on-demand video is designed for health care professionals (cardiologists, endocrinologists, lipidoligists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment and clinical management in reducing cardiovascular events with Icosapent Ethyl-Intervention.

Prof. Deepak Bhatt

First published: March 26, 2022  

In these KOL masterclass on-demand videos, Prof. Lale Tokgözoğlu discusses Atherosclerotic Cardiovascular Disease (ASCVD) and dyslipidemia in female patients with emphasis on female specific risks, course, and management of the disease. She answers questions received from the audience during the live webinar. This video is designed for health care professionals (cardiologists, endocrinologists, lipidogists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with a history and risk of ASCVD.

Prof. Lale Tokgözoğlu

First published: March 7, 2022  

Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.

To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.

Prof. Christopher Cannon, Prof. Kausik Ray

First published: January 10, 2022  

Prof. Lale Tokgözoğlu and Prof. Chern-En Chiang summarize the year in Lipids and discuss the highlights from this year’s AHA Scientific Sessions, as well as recent advances in diabetes treatment in patients with ASCVD

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

A Peer-to-Peer Discussion

In this specially compiled video, Dr. Carl Orringer, a past president of the National Lipid Association (NLA), shares his views on the recently published NLA Scientific Statement on Lipid Measurements in the Management of Cardiovascular Diseases in a conversation with our Editorial Panel Member, Prof. Lale Tokgözoğlu. The experts discuss the importance of these lipoprotein measurements to clinicians and other healthcare professionals providing treatment and the importance of shared decision making (SDM) in improving patient care.

Prof. Lale Tokgözoğlu, Dr. Carl Orringer

First published: October 21, 2021  

A comprehensive summary of the highlights from ESC Congress 2021 in ASCVD and lipidology. In the first specially compiled video, Professor Cannon and Professor Bhatt share their views on the late breaker results from REDUCE-IT and OMENI trials, along with the update ESC prevention guidelines. In the second video, Professor Cannon and Professor Nicholls discuss late-breaking results from the HUGYENs trial on evolcoumab, as well as the ESC prevention guidelines and the impact of the NHS approval of Inclisiran in improving patient care.

Christopher Cannon, MD & Dr. Deepak L. Bhatt MD, MPH & Professor Stephen Nicholls, MBBS, Ph.D., FRACP, FACC, FESC, FAHA, FCSANZ, FAHMS

First published: September 16, 2021